Results 311 to 320 of about 1,678,607 (395)

Growth Hormone Receptor Antagonists

Neuroendocrinology, 2006
The currently available long-acting somatostatin analogs normalize serum growth hormone (GH) levels and insulin-like growth factor-I levels in approximately 60% of patients with acromegaly. The recently introduced GH receptor antagonist, pegvisomant, is able to normalize insulin-like growth factor-I levels in virtually all acromegalic subjects ...
van der Lely, AJ (Aart-Jan), Kopchick, JJ   +1 more
openaire   +3 more sources

Gonadotropin-releasing-hormone-receptor antagonists

The Lancet, 2001
Pulsatile gonadotropin-releasing hormone (GnRH) stimulates the pituitary secretion of both luteinising hormone (LH) and follicle-stimulating hormone (FSH) and thus controls the hormonal and reproductive function of the gonads. Blockade of GnRH effects may be wanted for a variety of reasons-eg, to prevent untimely luteinisation during assisted ...
J A, Huirne, C B, Lambalk
openaire   +2 more sources

Calcium Antagonists and Hormone Release

Clinical Science, 1984
Introduction: Calcium (Ca2+) has been aptly entitled the ‘universal provocateur’ [1] in recognition of its many indispensable metabolic actions. The class of drugs popularly known as calcium antagonists (calcium slow channel blockers) provokes a variety of pharmacological effects and these drugs are useful as probes of calcium-dependent mechanisms. One
Millar, J. A., Struthers, A. D.
openaire   +3 more sources

Antagonists of Growth Hormone-Releasing Hormone in Oncology

Combinatorial Chemistry & High Throughput Screening, 2006
The development of antagonists of growth hormone (GH) - releasing hormone (GH-RH) is reviewed. GH-RH antagonists bind with a high affinity to pituitary receptors for GH-RH and inhibit the release of GH in vitro and in vivo. The main applications of GH-RH antagonists would be for tumor therapy.
Andrew V, Schally, Jozsef L, Varga
openaire   +2 more sources

Combining Growth Hormone-Releasing Hormone Antagonist With Luteinizing Hormone-Releasing Hormone Antagonist Greatly Augments Benign Prostatic Hyperplasia Shrinkage

Journal of Urology, 2012
Benign prostatic hyperplasia often affects aging men. Antagonists of the neuropeptide growth hormone-releasing hormone reduced prostate weight in an androgen induced benign prostatic hyperplasia model in rats. Luteinizing hormone-releasing hormone antagonists also produce marked, protracted improvement in lower urinary tract symptoms, reduced prostate ...
Ferenc G, Rick, Luca, Szalontay, Andrew V, Schally, Norman L, Block, Mehrdad, Nadji, Karoly, Szepeshazi, Irving, Vidaurre, Marta, Zarandi, Magdolna, Kovacs, Zoltan, Rekasi   +9 more
openaire   +2 more sources

Antagonists of Trophic Hormones

Gynecologic and Obstetric Investigation, 1971
Antagonists of pituitary trophic hormones may act either by inhibiting the synthesis and release of the hormone, by interfering with the interaction of the trophic hormone with its target tissue, or by inhibiting the intracellular response of the target cell.
openaire   +2 more sources

Steroid Hormones, Receptors, and Antagonists

Annals of the New York Academy of Sciences, 1996
In the thirty-odd years since the first demonstration of estrogen-binding components in reproductive tissues, much has been learned about the molecular details of steroid hormone action. Facts still to be elucidated include the precise mechanism by which interaction with the steroid disrupts the native receptor complex to generate an active ...
openaire   +2 more sources

Luteinizing hormone–releasing hormone antagonists in prostate cancer

Urology, 2001
Luteinizing hormone-releasing hormone (LHRH) antagonists work by directly inhibiting LHRH without any initial stimulation of the LHRH receptor. The physiologic response is a direct and rapid decrease in luteinizing hormone, follicle-stimulating hormone, and testosterone without any flare.
openaire   +2 more sources

Growth hormone secretagogue receptor antagonists.

Expert opinion on therapeutic patents, 2012
The patent claims peptidic/nonpeptidic inhibitors of the ghrelin receptor, the growth hormone secretagogue receptor (GHSR) 1A. Among these compounds, it was disclosed that the addition in some compounds of a GlyMetAla tripeptide at the N-terminus of the ghrelin peptide agonists converts them into ghrelin receptor antagonists.
openaire   +2 more sources

Antineoplastic Action of Growth Hormone-Releasing Hormone (GHRH) Antagonists

Recent Patents on Anti-Cancer Drug Discovery, 2012
Some of the antagonists of growth hormone-releasing hormone (GHRH) are able to inhibit the growth of various experimental human cancers. The antitumor effects of first antagonists seemed to be dependent mainly on the disruption of pituitary secretion of growth hormone (GH), followed by the reduction in the levels of circulating insulin-like growth ...
Agnieszka, Siejka, Hanna, Lawnicka, Gabriela, Melen-Mucha, Ewelina, Motylewska, Jan, Komorowski, Henryk, Stepien   +5 more
openaire   +2 more sources